Skip to main content
Erschienen in: Clinical Autonomic Research 4/2023

13.05.2023 | Research Article

Cancer in pathologically confirmed multiple system atrophy

verfasst von: William P. Cheshire, Shunsuke Koga, Philip W. Tipton, Hiroaki Sekiya, Owen A. Ross, Ryan J. Uitti, Keith A. Josephs, Dennis W. Dickson

Erschienen in: Clinical Autonomic Research | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to assess whether cancer occurs with increased frequency in multiple system atrophy (MSA). The pathological hallmark of MSA is glial cytoplasmic inclusions containing aggregated α-synuclein, and the related protein γ-synuclein correlates with invasive cancer. We investigated whether these two disorders are associated clinically.

Methods

Medical records of 320 patients with pathologically confirmed MSA seen between 1998 and 2022 were reviewed. After excluding those with insufficient medical histories, the remaining 269 and an equal number of controls matched for age and sex were queried for personal and family histories of cancer recorded on standardized questionnaires and in clinical histories. Additionally, age-adjusted rates of breast cancer were compared with US population incidence data.

Results

Of 269 cases in each group, 37 with MSA versus 45 of controls had a personal history of cancer. Reported cases of cancer in parents were 97 versus 104 and in siblings 31 versus 44 for MSA and controls, respectively. Of 134 female cases in each group, 14 MSA versus 10 controls had a personal history of breast cancer. The age-adjusted rate of breast cancer in MSA was 0.83%, as compared with 0.67% in controls and 2.0% in the US population. All comparisons were nonsignificant.

Conclusion

The evidence from this retrospective cohort found no significant clinical association of MSA with breast cancer or other cancers. These results do not exclude the possibility that knowledge about synuclein pathology at the molecular level in cancer may lead to future discoveries and potential therapeutic targets for MSA.
Literatur
7.
Zurück zum Zitat Sugier PE, Lucotte EA, Domenighetti C et al. (2023) Comprehensive unbiased risk factor assessment for genetics and environment in Parkinson’s disease (Courage-PD) consortium; Truong T ,Elbaz A. Investigation of shared genetic risk factors between Parkinson’s disease and cancers. Mov Disord. https://​doi.​org/​10.​1002/​mds.​29337 CrossRefPubMed Sugier PE, Lucotte EA, Domenighetti C et al. (2023) Comprehensive unbiased risk factor assessment for genetics and environment in Parkinson’s disease (Courage-PD) consortium; Truong T ,Elbaz A. Investigation of shared genetic risk factors between Parkinson’s disease and cancers. Mov Disord. https://​doi.​org/​10.​1002/​mds.​29337 CrossRefPubMed
12.
Zurück zum Zitat Wüllner U, Schmitz-Hübsch T, Abele M, Antony G, Bauer P, Eggert K (2007) Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German competence network on Parkinson’s disease. J Neural Transm (Vienna) 114(9):1161–1165. https://​doi.​org/​10.​1007/​s00702-007-0746-0 CrossRefPubMed Wüllner U, Schmitz-Hübsch T, Abele M, Antony G, Bauer P, Eggert K (2007) Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German competence network on Parkinson’s disease. J Neural Transm (Vienna) 114(9):1161–1165. https://​doi.​org/​10.​1007/​s00702-007-0746-0 CrossRefPubMed
29.
Zurück zum Zitat Ji H, Liu YE, Jia T et al. (1997) Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 57(4):759–764 PubMed Ji H, Liu YE, Jia T et al. (1997) Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 57(4):759–764 PubMed
35.
Zurück zum Zitat Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK (2000) Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88(9):2154–2163 CrossRefPubMed Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK (2000) Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88(9):2154–2163 CrossRefPubMed
59.
Zurück zum Zitat Min L, Zhang C, Ma R, Li X, Yuan H, Li Y, Chen R, Liu C, Guo J, Qu L, Shou C (2016) Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients. BMC Cancer 16(1):717 CrossRefPubMedPubMedCentral Min L, Zhang C, Ma R, Li X, Yuan H, Li Y, Chen R, Liu C, Guo J, Qu L, Shou C (2016) Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients. BMC Cancer 16(1):717 CrossRefPubMedPubMedCentral
Metadaten
Titel
Cancer in pathologically confirmed multiple system atrophy
verfasst von
William P. Cheshire
Shunsuke Koga
Philip W. Tipton
Hiroaki Sekiya
Owen A. Ross
Ryan J. Uitti
Keith A. Josephs
Dennis W. Dickson
Publikationsdatum
13.05.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Autonomic Research / Ausgabe 4/2023
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-023-00946-w

Weitere Artikel der Ausgabe 4/2023

Clinical Autonomic Research 4/2023 Zur Ausgabe